文献速递眼底病与葡萄膜炎

地塞米松植入剂治疗糖尿病性黄斑水肿的欧洲多中心回顾性研究

A Collaborative Retrospective Study on the Efficacy and Safety of Intravitreal Dexamethasone Implant (Ozurdex) in Patients with Diabetic Macular Edema: The European DME Registry Study.
PubMed 文献 · Ophthalmology · 2019-10-10

这项欧洲多中心回顾性队列研究分析了340只糖尿病性黄斑水肿眼接受地塞米松植入剂(Ozurdex)的真实世界疗效与安全性。每针分析显示22.7%的眼视力提高≥15个字母,平均达峰时间81.9±39.7天,中央黄斑厚度平均最大减少174±171μm,眼压>25mmHg发生于7.9%的注射后,未报告眼内炎。早期DME、血糖控制良好及初治患者获益更明显。

要点

  • 每针分析中22.7%的眼BCVA提高≥15个字母,37.8%提高≥10个字母。
  • 平均视力改善达峰时间81.9±39.7天,中央黄斑厚度平均最大减少174±171μm。
  • 眼压>25mmHg发生于7.9%的注射后,未报告眼内炎,总体安全性良好。

核心结论

  • 地塞米松植入剂是糖尿病性黄斑水肿有效且安全的治疗,视力改善在注射后约3个月达峰后消退。
  • 临床医生和提供者可考虑缩短治疗间隔以维持疗效。

研究设计与样本

  • 多中心回顾性队列研究,纳入8个国家25个临床中心的287例患者共340只糖尿病性黄斑水肿眼。
  • 数据分析采用每针视角(762针,以注射日为基线评估单次注射药效学)和注射序列视角(171只眼的171个序列共444针,序列定义为2次及以上注射且间隔3至6个月,分析末次注射后3至6个月结局)。
  • 注射序列分析的平均随访时间为1.7±0.8年。

主要发现

  • 每针分析的762针中,22.7%达到BCVA提高≥15个字母,37.8%达到提高≥10个字母,7.6%视力下降≥15个字母。
  • 平均视力改善达峰时间81.9±39.7天,中央黄斑厚度平均最大变化为-174±171μm。
  • 早期DME眼较晚期DME眼更多达到BCVA提高≥10个字母(47.4% vs. 33.9%,P=0.001),更少出现视力下降≥10个字母(8.2% vs. 13.5%,P=0.029)。
  • 血糖控制良好的患者中央黄斑厚度下降更显著(P=0.0002)。
  • 初治患者达到BCVA提高≥10个字母和≥15个字母的比例更高(分别为P=0.001和P=0.006)。

关键数值与推荐

  • 主要结局为BCVA较基线提高≥15个字母。
  • 次要结局包括BCVA提高≥10个字母、中央黄斑厚度变化、达峰时间及安全性。
  • 眼压>25mmHg发生于7.9%的注射后,未报告眼内炎。

临床怎么用

  • 地塞米松植入剂可用于真实世界糖尿病性黄斑水肿患者,早期DME、血糖控制良好及初治患者可能获益更多。
  • 因视力改善约在注射后3个月达峰后消退,可考虑缩短治疗间隔以维持疗效。
  • 注射后需监测眼压,眼压>25mmHg的发生率约为7.9%。

局限性

  • 回顾性研究设计可能存在选择偏倚和信息偏倚。
  • 每针分析以注射日为基线,可能受前一针残余效应影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To evaluate the efficacy, effect profile, and safety of dexamethasone implant on diabetic macular edema (DME) in a real-life setting, further comparing results by DME duration, previous treatment status, and diabetic control. DESIGN: A multicenter, retrospective cohort of 340 DME eyes of 287 patients from 25 clinical sites from 8 countries. METHODS: Data were analyzed in 2 perspectives: per injection, in which all measurements were grouped and baseline was defined as the day of injection, and thus the pharmacodynamics of single injections could be assessed; and injection series, defined as 2 or more injections with 3 to 6 months between injections analyzing the outcome 3 to 6 months after the last injection. MAIN OUTCOME MEASURES: Primary outcome was improvement of 15 or more letters in best-corrected visual acuity (BCVA) from baseline. Secondary outcomes included improvement of 10 letters or more in BCVA, change in central macular thickness (CMT), and time to maximum improvement and safety. RESULTS: Overall, 762 injections were administered to 340 eyes of 287 patients. Injection series analysis included 171 series in 171 eyes of 150 patients, for a total of 444 injections, with a mean follow-up of 1.7±0.8 years. Of the 762 injections analyzed per injection, 22.7% achieved a 15-letter or more improvement, and 37.8% achieved a 10-letter or more improvement. Mean time to peak improvement was 81.9±39.7 days. Mean maximum change in CMT was -174±171 μm. Overall, 7.6% lost 15 or more letters. More eyes with early DME gained 10 or more letters and fewer eyes lost 10 or more letters compared with eyes with late DME (47.4% vs. 33.9% [P = 0.001] and 8.2% vs. 13.5% [P = 0.029], respectively). Patients with controlled diabetes showed greater CMT reduction (P = 0.0002). A higher percentage of treatment-naive patients gained 10 or 15 letter or more in BCVA (P = 0.001 and P = 0.006, respectively). Intraocular pressure elevation of more than 25 mmHg was found following 7.9% of injections; no endophthalmitis was reported. CONCLUSIONS: Dexamethasone implant is an effective and safe treatment for DME. Peak improvement was achieved 3 months after injection and dissipated thereafter. Clinicians and providers may consider shortening treatment intervals.

来源:Ophthalmology,查看原文。版权归原作者所有。

引用

  1. Rosenblatt A, Udaondo P, Cunha-Vaz J, et al. A Collaborative Retrospective Study on the Efficacy and Safety of Intravitreal Dexamethasone Implant (Ozurdex) in Patients with Diabetic Macular Edema: The European DME Registry Study. Ophthalmology. 2019. PMID: 31932090. doi:10.1016/j.ophtha.2019.10.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。